Table 3.

Key efficacy endpoints by treatment in the DB study [ITT population].

	Placebo [n = 42]	Etrasimod 1 mg [n = 38]	Etrasimod 2 mg [n = 32]	Overall [n = 112]	Placebo [n = 42]	Etrasimod 1 mg [n = 38]	Etrasimod 2 mg [n = 32]	Overall [n = 112]
Efficacy outcome	Week 12				End of treatment
Patients with clinical response
n [%] 90% CI	13 [31.0] 19.4, 44.6	16 [42.1] 28.5, 56.7	17 [53.1] 37.3, 68.5	46 [41.1] 33.2, 49.3	25 [59.5] 45.7, 72.3	28 [73.7] 59.5, 85.0	19 [59.4] 43.3, 74.0	72 [64.3] 56.2, 71.8
Patients with clinical remission
n [%] 90% CI	4 [9.5] 3.3, 20.5	6 [15.8] 7.1, 28.8	15 [46.9] 31.5, 62.7	25 [22.3] 16.0, 29.8	12 [28.6] 17.4, 42.1	14 [36.8] 23.8, 51.5	11 [34.4] 20.6, 50.4	37 [33.0] 25.7, 41.1
Patients with endoscopic improvement
n [%] 90% CI	7 [16.7] 8.1, 29.0	8 [21.1] 10.9, 34.8	16 [50.0] 34.4, 65.6	31 [27.7] 20.8, 35.5	15 [35.7] 23.5, 49.5	20 [52.6] 38.2, 66.7	13 [40.6] 26.0, 56.7	48 [42.9] 34.9, 51.1

All patients received etrasimod 2 mg during the OLE. Groups are based on treatment during the DB period. The overall group includes patients who received any treatment [placebo, etrasimod 1 mg, or etrasimod 2 mg] during the DB period. Week 12 was the end of the DB period. The ITT population included all patients who received any etrasimod 2 mg during the OLE. In the NRI analysis, data missing due to any reason, including study discontinuation, were imputed as non-response. 90% CI are exact CI for the % of patients with the given endpoint.

CI, confidence interval; DB, double-blind; n, number of patients; NRI, non-responder imputation; OLE, open-label extension; ITT, intention-to-treat.